UCB (OTCMKTS:UCBJF) Shares Gap Down – Here’s Why

UCB SA (OTCMKTS:UCBJF) gapped down before the market opened on Monday . The stock had previously closed at $269.84, but opened at $255.52. UCB shares last traded at $255.52, with a volume of 525 shares.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on UCBJF shares. Jefferies Financial Group upgraded shares of UCB to a “hold” rating in a research report on Monday, August 3rd. Piper Sandler restated a “neutral” rating on shares of UCB in a research report on Wednesday, July 22nd. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy”.

UCB Stock Down 1.2%

The business’s fifty day moving average is $290.62 and its two-hundred day moving average is $298.55. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.